Colchicine Use Is Associated with Shorter Intensive Care Unit Stay and Lower Fresh Frozen Plasma Transfusion Requirements After Coronary Artery Bypass Grafting
Preprint
- 6 August 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Colchicine has demonstrated anti-inflammatory and cardiovascular benefits in patients with coronary heart disease. However, evidence regarding its effects on postoperative inflammation and early clinical outcomes following coronary artery bypass grafting (CABG) remains limited. Objective: To evaluate the association between perioperative low-dose colchicine use and postoperative clinical outcomes, transfusion requirements, complications, and inflammatory markers in patients undergoing elective on-pump CABG. Methods: This retrospective study included 151 patients who underwent elective on-pump CABG: 81 received colchicine (0.5 mg once daily for 3 days preoperatively and 10 days postoperatively), and 70 did not receive colchicine. The primary clinical outcomes included ICU and total hospital length of stay, erythrocyte and fresh frozen plasma (FFP) transfusion requirements, wound infection, and surgical revision. Postoperative day 5 laboratory parameters included C-reactive protein, white blood cell (WBC) count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and albumin. Between-group comparisons were performed using Student’s or Welch’s t test and Pearson’s chi-square or Fisher’s exact test, as appropriate. Results: Baseline age and sex distribution were similar between the groups. The colchicine group had a significantly shorter ICU stay than the control group (4.28±1.95 vs 5.83±3.04 days; mean difference, −1.54 days; 95% CI, −2.38 to −0.71; P< 0.001). FFP transfusion requirements were also significantly lower in the colchicine group (3.49±1.24 vs 8.13±3.97 units; mean difference, −4.63 units; 95% CI, −5.62 to −3.65; P< 0.001). Postoperative WBC counts were lower with colchicine (9.44±3.31 vs 10.78±4.04×10⁹/L; P=0.027). Total hospital stay, erythrocyte transfusion requirements, other inflammatory parameters, wound infection rates, and surgical revision rates did not differ significantly between the groups. Conclusion: Perioperative low-dose colchicine use was associated with shorter ICU stays, lower FFP transfusion requirements, and reduced postoperative WBC counts following elective on-pump CABG. Prospective randomized studies are required to confirm these findings and determine whether colchicine improves early postoperative outcomes.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of PericarditisJACC, 2025
- Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgeryAmerican Heart Journal Plus: Cardiology Research and Practice, 2025
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary SyndromesJACC, 2025
- 2024 ESC Guidelines for the management of chronic coronary syndromesEuropean Heart Journal, 2024
- 2023 ESC Guidelines for the management of acute coronary syndromesEuropean Heart Journal, 2023
- Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine, 2020
- Efficacy and Safety of Low-Dose Colchicine after Myocardial InfarctionNew England Journal of Medicine, 2019
- PCI and CABG for Treating Stable Coronary Artery DiseaseJACC, 2019
- Colchicine—Update on mechanisms of action and therapeutic usesSeminars in Arthritis and Rheumatism, 2015
- Low-Dose Colchicine for Secondary Prevention of Cardiovascular DiseaseJACC, 2013